659 AN SINGLE-ARM OPEN-LABEL PHASE II STUDY OF CAMRELIZUMAB PLUS APATINIB AS SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA

• Published in: Diseases of the esophagus Vol. 34; no. Supplement_1
• Main Authors: Wang, Feng, Fan, Qingxia, Wang, Junsheng, Wu, Tao, Hong, Yonggui, Meng, Xiangrui, Ren, Zhonghai, Guo, Yanzhen, Yang, Xiuli, Shi, Pei, Yang, Jiamei, Yin, Xianzhe, Luo, Zhiquan, Xia, Jin, Zhou, Yue, Liu, Enjie, Jiang, Guozhong
• Format: Journal Article
• Language: English
• Published: 17.09.2021

Abstract   Esophageal squamous cell carcinoma (ESCC) as a common malignancy is prevalent in East Asia and in eastern and southern Africa. Although pembrolizumab, nivolumab and camrelizumab are respectively recommended as second-line treatment for advanced ESCC due to improved overall survival (OS),...